

Accepted Manuscript

Discovery and Structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway

Hongna Wu, Jun Wu, Wenxuan Zhang, Zhongwen Li, Jinhui Fang, Xu Lian, Tong Qin, Hao Jie, Qi Zhou, Song Wu

PII: S0960-894X(19)30083-6
DOI: <https://doi.org/10.1016/j.bmcl.2019.02.009>
Reference: BMCL 26289

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 24 December 2018
Revised Date: 28 January 2019
Accepted Date: 7 February 2019

Please cite this article as: Wu, H., Wu, J., Zhang, W., Li, Z., Fang, J., Lian, X., Qin, T., Jie, H., Zhou, Q., Wu, S., Discovery and Structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway, *Bioorganic & Medicinal Chemistry Letters* (2019), doi: <https://doi.org/10.1016/j.bmcl.2019.02.009>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Discovery and Structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway

Hongna Wu^{a,#}, Jun Wu^{b,c,#}, Wenxuan Zhang^{a,#,*}, Zhongwen Li^{b,d}, Jinhui Fang^{b,c}, Xu Lian^a, Tong Qin^a, Hao Jie^{b,c}, Qi Zhou^{b,c}, Song Wu^{a,*}

a. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

b. State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China

c. Beijing Stem Cell Bank, Institute of Zoology, Chinese Academy of Sciences, Beijing 100192, China

d. University of Chinese Academy of Sciences, Beijing 100049, China

#These three authors contributed equally to this work.

Corresponding Author*email: wxzhang@imm.ac.cn; ws@imm.ac.cn

Abstract

Aberrant Wnt signaling has been implicated in a variety of disease. Inhibition of the Wnt pathway is an attractive approach for developing new therapeutics for the treatment of various types of fibrosis and cancers. We have discovered the phthalimide-phenylpyridine conjugate as a novel hit compound for the Wnt pathway inhibitors from cellular screening. The structure-activity relationship of these compounds suggested both of the substituent group on the phthalimide fragment and the structure of the linker were critical to the inhibitory activity. The most potent compound was about 10-folds more potent than the hit compound, with IC₅₀ value of 0.28±0.01 μM.

Key words

Wnt signaling pathway, Phthalimide-phenylpyridine conjugate, Structure-activity relationship

The Wnt signaling pathway is a critical developmental pathway which controls cellular functions such as proliferation and differentiation.^{1,2,3} Extracellular Wnt can trigger the canonical Wnt/β-catenin dependent pathway, the noncanonical Wnt/Ca²⁺ and Planar Cell Polarity pathway (PCP). The β-catenin dependent signaling pathway

is activated by the binding of Wnt ligand to the low-density lipoprotein receptor (LRP-5/6 receptors) and Frizzled receptors. This in turn activates Disheveled protein (Dvl), which inhibits Axin-mediated β -catenin phosphorylation, resulting in accumulation of cytoplasmic β -catenin. The β -catenin migrates to the nucleus, interacting there with T cell-specific factor (TCF)/lymphoid enhancer binding factor (LEF) and co-activators, to turn on the Wnt target genes such as c-Myc, cyclin D1 and Cdkn1.

Aberrant Wnt signaling has been implicated in a variety of disease, such as degenerative diseases, metabolic diseases and cancer.⁴ In several types of malignancy, Wnt signaling contribute to the maintenance of the cancer stem cell (CSC) population.⁵ Inhibition of the Wnt pathway is an attractive approach for developing new therapeutics for the treatment of various types of fibrosis and cancers.^{6,7} Several types of Wnt-signaling inhibitors are under ongoing development as anticancer therapies, including Porcupine inhibitors^{8,9}, β -Catenin-destruction complex inhibitors such as Tankyrase inhibitors^{10,11} and Disheveled inhibitors¹², TCF/ β -catenin transcription complex inhibitors¹³ and CREB-binding protein (CBP)/ β -catenin antagonist¹⁴. The Porcupine inhibitors LGK974⁸ and CBP/ β -catenin antagonist PRI-724 are now in clinical trails for the treatment of cancers (**Fig 1**).




Figure 1 The structure of LGK974 and PRI-724

Herein, we describe the identification of phthalimide-phenylpyridine conjugate as a novel Wnt inhibitor from cellular screening. With the L-Wnt3A cell line that contains a luciferase reporter for β -catenin mediated transcriptional activation reported by Lum and co-workers,⁶ we screened the synthetic small-molecule library in our lab. Fortunately, one compound (**1**) showed modest inhibitory activity (34%) at 10 μ M in the assay (**Fig 2**), which has a phthalimide and phenylpyridine fragment, linked by a carbon chain. There are few similar compounds and biological activity reported, so it is worthy to study their structure-activity relationship.





Figure 1 The structure of hit compound **1**

At first, the modifications on the phthalimide fragment were carried out (**Scheme 1**). The derivatives of the compound **1** were synthesized via a two-step amide coupling reactions from the commercially available precursor phthalic anhydrides. In the first step, the phthalic anhydrides coupled with 1, 4- aminobutyric acid in the presence of the acetic acid at 120 °C to afford the immediate **III**. This compound was pre-activated by the HATU, followed by the coupling reaction with 2-amino-5-phenylpyridine, giving the final phthalimide-phenylpyridine conjugates in 29~67% yields.



Scheme 1. The synthetic route of compounds

With the LGK 974 as the positive control agent, these compound were assayed in the L-Wnt3A-luciferase reporter system.¹⁵ Some derivatives showed modest inhibition ratio at 10 μM in this assay (**Table 1**). It is clear that the substitutions and their positions on the phthalimide fragment had great effects on the biological activity. The conjugates with halogen and methyl group at 3-position (**3**, **7**, **14**) were more potent than that with substitutions at 4-group (**2**, **6**, **13**, **15**, **16**). By contrast, both of the derivatives with the strong electron-withdraw nitro group at 3- or 4-position (**11** or **12**) showed weaker biological activity. Similarly, the extra halogen-substitutions of the 3- or 4-halogenated compounds (**4**, **5**, **8**, **9**) decreased the inhibitory activity of the Wnt signaling pathway. Among these phthalimide-phenylpyridine conjugates, the electron-donating 3-methyl derivatives (**14**) showed the best inhibitory activity, with IC₅₀ value of 2.79 \pm 0.01 μM in the cell assay. These results suggested that the electrical property of the phthalimide fragment played the important effect on the Wnt


pathway inhibitory activity, possibly by the adjustment the electronegativity of the 1-carbonyl group which may provide a hydrogen-bonding acceptor to the target. In additions, the stereo-hindrance effect also had great influence, thus compound **16** with Phenylacetylenyl group on 4-position showed weaker inhibitory rate than the methyl and butyl derivatives **13** and **15**.

Table 1. Wnt signaling pathway inhibitory activity of synthesized compounds

Comp	R	Yield/%	Inhibition ratio /%
1	H	68	34
2	4-F	40	20
3	3-F	40	44
4	3,4-F	41	21
5	3,6-F	40	37
6	4-Cl	55	22
7	3-Cl	52	46
8	4,5-Cl	68	-8
9	2,3,4,5-Cl	69	-5
10	4-Br	55	18
11	4-NO ₂	58	19
12	3-NO ₂	57	17
13	4-Me	50	20
14	3-Me	52	61
			(IC ₅₀ =2.79±0.01 μM)
15	4-butyl	57	23
16	4-Phenylacetylenyl	34	7
LGK 974			93
			(IC ₅₀ =0.57±0.28 nM)

The structure of linker between the phthalimide and phenylpyridine fragments was then explored. With the similar synthetic methods as compounds **1**, the modified derivatives of the lead compound **14** with different linkers were prepared (**Scheme 2**).

As expected, the length of the linker had great influences on the biological activities (**Table 2**). By the decrease of the number of the carbon atoms from 3 to 2, the conjugate **17** showed much less inhibitory activity. By contrast, compound **18** with a one carbon-linker was about 10-folds more potent than conjugate **14**, with IC_{50} value of $0.28 \pm 0.01 \mu\text{M}$. However, when the linker was replaced by ethylidene, the inhibitory rate of the compound **19** was reduced significantly. The difference of the biological activity of these conjugates with different linker possibly because of the change of the conformation of the molecules. Assumedly, the compound **18** may adopt the relatively appropriated conformation to bind with the target, but the conformation of the compound **17** is different. For compound **19**, the linker has a chirality center, leading to each mesomer adopts the opposite conformation, so they showed about half inhibitory rate of compound **18**.



a:HOAC,120°Φ: HATU, TEA, DCM, r.t

Scheme 2. The synthetic route of compounds

Table 2. Wnt signaling pathway inhibition activity of synthesized compounds

Comp	X	Yield/%	inhibition ratio /%	$IC_{50}/\mu\text{M}$
17	-CH ₂ CH ₂ -	54	29	>10
18	-CH ₂ -	52	76	0.28 ± 0.01^a
19	-CH(CH ₃)-	48	39	>10

^a $IC_{50} = \text{Mean} \pm \text{S.E. (n=3)}$

In conclusion, we have discovered the phthalimide-phenylpyridine conjugate as a promising new chemotype for the Wnt pathway inhibitors. The structure-activity relationship of these compounds suggested both of the substituent group on the phthalimide fragment and the structure of the linker were critical to the inhibitory

activity. Derivative **18** was the most potent compound to inhibit the Wnt signaling, which will be studied and evaluated in the future.


ASSOCIATED CONTENT

Supporting Information

ACKNOWLEDGMENTS

We thank The National Natural Science Fund (81602958), 973 Program (2015CB964803), The Drug Innovation Major Project (2018ZX09711001-005) and CAMS Innovation Fund for Medical Sciences (CIFMS 2017-I2M-2-004) for financial support.

Graphics



- 1 Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell* 2006, 127, 469–480.
- 2 Takebe N, Miele L, Harris P J, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nat Rev Clin Oncol*, 2015, 12(8): 445.
- 3 Behrens J. Control of β -catenin signaling in tumor development. *Ann. N. Y. Acad. Sci.* 2000, 910, 21–33.
- 4 Clevers H, Nusse R. Wnt/ β -catenin signaling and disease. *Cell*, 2012, 149(6): 1192-1205.
- 5 Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. *Nat. Rev. Cancer* 2012, 12, 133–143.
- 6 Chen B, Dodge M E, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. *Nat Chem Biol*, 2009, 5(2): 100.
- 7 Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. *Cancer Treat Rev*, 2018, 62: 50-60.
- 8 Liu J, Pan S, Hsieh M H, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proc. Natl. Acad. Sci. U. S. A.* 2013, 110: 20224–20229.
- 9 Madan B, Ke Z, Harmston N, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. *Oncogene*, 2016, 35(17): 2197.
- 10 Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. *Nat Rev Drug Discov*, 2012, 11(12):923–36.
- 11 Tian XH, Hou WJ, Fang Y, et al. XAV939, a tankyrase 1 inhibitor, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/ β -catenin signaling pathway. *J Exp Clin Canc Res*, 2013, 32(1): 100.

-
- 12 Fujii N, You L, Xu Z, et al. An antagonist of dishevelled protein-protein interaction suppresses β -catenin-dependent tumor cell growth. *Cancer Res*, 2007, 67(2): 573-579.
 - 13 Lepourcelet M, Chen Y N P, France D S, et al. Small-molecule antagonists of the oncogenic Tcf/ β -catenin protein complex. *Cancer cell*, 2004, 5(1): 91-102.
 - 14 Lenz H J, Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. *Cancer Sci*, 2014, 105(9): 1087-1092.

ACCEPTED MANUSCRIPT